Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C

Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C

BACKGROUND: Patients with substance use disorders (SUD) and chronic hepatitis C virus infection (HCV) have limited access to direct-acting antivirals (DAAs) due to multilevel issues related to providers (eg, concern about reinfection); patients (eg, refusal); payers (eg, prior authorization); and he...

Full description

Bibliographic Details
Main Authors: Diaby, V. (Author), Jiang, X. (Author), Lo-Ciganic, W. (Author), Park, H. (Author), Parker, R. (Author), Vouri, S.M (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
adolescent
Adolescent
adult
Adult
aged
Aged
alcohol liver disease
alcoholism
ambulatory care
Antiviral Agents
antiviral therapy
antivirus agent
Article
buprenorphine
cardiovascular disease
chronic hepatitis C
chronic kidney failure
chronic obstructive lung disease
cohort analysis
comorbidity
controlled study
cost
depression
diabetes mellitus
drug dependence
dyslipidemia
economics
emergency ward
epilepsy
female
Female
follow up
health care cost
Health Care Costs
health care utilization
hepatitis A
Hepatitis A virus
Hepatitis B virus
hepatitis C
Hepatitis C, Chronic
hospitalization cost
human
Humans
hypertension
insurance
Insurance Claim Review
liver cirrhosis
long term care
major clinical study
male
Male
medical service
medicare
Medicare
methadone
middle aged
Middle Aged
nonalcoholic fatty liver
opiate addiction
Patient Acceptance of Health Care
patient attitude
practice guideline
pregnancy
Retrospective Studies
retrospective study
schizophrenia
Substance-Related Disorders
United States
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items